numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based medicine.
Our diagnostic test are based on the interpretation of biomarker in the metabolism, whose dynamics and relation to each other allow for predicting disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful at manageable costs.
FDA Submission of AXINON® GFR(NMR)
President at numares GROUP Corp.